Skip to main content
UniHealth

Doctor search

Rahul Khurana, MD

Ophthalmology · Mountain View

NPI 1912002106

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
27
6 carriers
Offices
3

Offices

3 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group

Looking this up.

Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.

Plans that list them

27 plans · 6 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khurana’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

27 of 27 plans

Plans whose provider directory lists this clinician
Alignment Health Advantage PPO (PPO)Alignment Health PlanListedOct 3, 2026
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Sutter Advantage +More (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Astiva Health C-SNP WOW - NorCal (HMO C-SNP)Astiva HealthListedSep 27, 2026
Astiva Health Premier Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Astiva Health Savings Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Blue Shield Inspire (HMO)Blue Shield of CaliforniaListedAug 26, 2026
Central Health Classic Care Plan III (HMO)Central Health Medicare PlanListedAug 15, 2026
Central Health Dual Access Plan (HMO D-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Embrace Care Plan (HMO C-SNP)Central Health Medicare PlanListed, may be out of dateSep 15, 2025
Central Health Embrace Choice Plan (HMO C-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Valor Care Plan (HMO)Central Health Medicare PlanListedAug 15, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A87255 · Current

Licensed to practise in California · since 2004 · expires 2028-05-31 · Duke University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Peninsula Medical Center
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.139BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.242BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.21 (0.27 to 2.15) · 1,258 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.81 (0.51 to 1.1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths155.44 (112.67 to 198.21) · 90 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.5 · 32 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 82 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 188 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9 · 473 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.8 · 342 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.4 · 485 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 3,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.4) · 6,904 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,052 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.41 (1.43 to 5.39) · 1,695 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.72 (0.17 to 3.28) · 665 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.66 to 3.56) · 1,545 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.1 (1.3 to 12.9) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.96 (2.63 to 9.29) · 653 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.15 to 3.08) · 418 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.14 (0 to 0.78) · 5,539 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.7 · 192 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.215No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.263No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.74No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.3 · 300 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19 · 702 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits1.2 · 207 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13.6 · 531 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits24.3 · 343 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.1 · 449 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.5 (2.8 to 7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits9.6 (6.7 to 13.7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 189 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11 · 45 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.6 · 117 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13 (9.7 to 17.2) · 584 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.2) · 764 casesNo differentJan 2024 – Dec 2024

What patients said (523 patients answered, 27% of those asked)

Patient survey stars by topic at Peninsula Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at Peninsula Medical Center
Room was "always" clean76%
Nurses "always" communicated well81%
Doctors "always" communicated well80%
Staff "always" explained58%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$2,467,099

Medicare paid this office $2,467,099 for 773 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection, aflibercept, 1 mg222$1,627,515None
Injection, faricimab-svoa, 0.1 mg14$174,982None
Injection of drug into eye251$162,689$113
Imaging of retina654$93,154$41
Short return visit (20+ min)406$79,389$87
See all 15 services
Every Original Medicare service billed
Injection, aflibercept, 1 mg222$1,627,515None
Injection, faricimab-svoa, 0.1 mg14$174,982None
Injection of drug into eye251$162,689$113
Imaging of retina654$93,154$41
Short return visit (20+ min)406$79,389$87
Return visit (30+ min)294$73,923$121
Injection, ranibizumab, 0.1 mg15$50,512None
Established patient complete exam of visual system315$39,548$116
Exam of retinal blood vessels using a special camera after injection of a dye180$36,876$174
New patient visit (45+ min)112$17,209$154
Photography of the retina230$12,141$38
New patient complete exam of visual system43$6,328$147
Established patient problem focused exam of visual system31$3,045$90
Extended exam of the back part of the eye with retinal drawing44$1,100$22
2d ultrasound scan of eye tissue and structures12$780$49

Procedures Medicare counted

Procedure volume Medicare published
Cataract surgery1-10None

Who their Medicare patients are

773 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 28% · Women 61% · Also on Medicaid 9% · Health risk score 1.21. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 75% · Diabetes 28% · Coronary heart disease 26% · Chronic kidney disease 25% · Atrial fibrillation 20% · Cancer 16% · Heart failure 14% · Depression 12% · COPD 8% · Stroke 8% · Dementia 7%.

The office billed $7,149,598, Medicare allowed $3,137,257 and paid $2,467,099; for 16,173 services of 43 kinds; $1,887,466 of it was for drugs given in the office and $579,633 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202477316,173791.21$7,149,598$2,467,099
202369413,555791.22$6,708,631$2,375,998
202267010,521791.24$7,256,014$2,655,323
202178511,008781.26$7,074,659$2,747,476
20206429,564791.45$6,118,171$2,371,943
201973311,042781.42$6,380,131$2,481,331
201882211,913781.44$6,253,899$2,426,006
201770710,398781.44$5,065,415$2,072,034
20166709,935781.34$3,520,756$1,732,234
20156959,170781.38$3,038,058$1,554,947
20146397,645781.32$2,499,854$1,418,259
20136966,754781.30$1,938,424$1,146,964

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 18 services

Original Medicare services billed in 2023
Injection, aflibercept, 1 mg195$1,628,209None
Injection of drug into eye232$148,019$106
Injection, faricimab-svoa, 0.1 mg14$127,457None
Injection, ranibizumab, 0.1 mg22$107,518None
Imaging of retina584$81,334$39
Return visit (30+ min)261$48,245$114
Established patient problem focused exam of visual system273$45,935$81
Short return visit (20+ min)291$38,432$87
Established patient complete exam of visual system268$31,870$108
Exam of retinal blood vessels using a special camera after injection of a dye161$28,167$139
Removal of membrane of retina with removal of internal limiting membrane of retina12$13,121$1,093
New patient visit (45+ min)91$12,487$137
Photography of the retina179$9,801$35
Destruction of leaking blood vessels of retina using laser15$5,030$314
New patient complete exam of visual system36$4,832$134
Compounded drug, not otherwise classified14$4,496None
Extended exam of the back part of the eye with retinal drawing37$874$20
2d ultrasound scan of eye tissue and structures12$536$45

2022: 17 services

Original Medicare services billed in 2022
Injection, aflibercept, 1 mg206$1,898,112None
Injection, ranibizumab, 0.1 mg30$201,040None
Injection of drug into eye255$166,664$104
Established patient problem focused exam of visual system374$90,024$84
Imaging of retina564$82,368$39
Return visit (30+ min)275$54,126$108
Established patient complete exam of visual system268$33,255$110
Exam of retinal blood vessels using a special camera after injection of a dye161$25,253$125
Removal of eye fluid (vitreous) between lens and retina15$10,877$640
New patient visit (45+ min)71$9,450$133
Photography of the retina142$8,018$35
Destruction of leaking blood vessels of retina using laser13$6,976$317
Compounded drug, not otherwise classified18$6,556None
New patient complete exam of visual system19$2,450$129
Short return visit (20+ min)16$1,416$79
Extended exam of the back part of the eye with retinal drawing44$1,045$22
2d ultrasound scan of eye tissue and structures14$629$42

2021: 18 services

Original Medicare services billed in 2021
Injection, aflibercept, 1 mg224$1,854,885None
Injection, ranibizumab, 0.1 mg37$276,628None
Injection of drug into eye292$171,300$107
Established patient problem focused exam of visual system329$101,949$87
Imaging of retina614$86,104$40
Return visit (30+ min)328$57,893$122
Established patient complete exam of visual system364$41,178$100
Exam of retinal blood vessels using a special camera after injection of a dye202$29,628$121
New patient visit (45+ min)135$19,680$146
Photography of the retina306$15,350$37
Compounded drug, not otherwise classified27$10,168None
Destruction of leaking blood vessels of retina using laser14$7,447$298
Photocoagulation treatment to prevent detachment of retina12$7,071$471
Short return visit (20+ min)65$6,520$89
Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye15$4,332$255
New patient complete exam of visual system20$2,954$148
Extended exam of the back part of the eye with retinal drawing56$1,465$23
2d ultrasound scan of eye tissue and structures20$1,345$48

2020: 14 services

Original Medicare services billed in 2020
Injection, aflibercept, 1 mg167$1,580,440None
Injection, ranibizumab, 0.1 mg45$288,570None
Injection of drug into eye217$126,686$93
Established patient problem focused exam of visual system276$112,202$85
Imaging of retina434$67,292$40
Established patient complete exam of visual system391$64,155$107
Exam of retinal blood vessels using a special camera after injection of a dye165$22,671$106
New patient visit (45+ min)139$19,045$137
Photography of the retina282$18,075$42
Destruction of leaking blood vessels of retina using laser12$8,768$337
Compounded drug, not otherwise classified16$7,774None
2d ultrasound scan of eye tissue and structures22$1,591$51
Extended exam of the back part of the eye with retinal drawing60$1,580$23
Short return visit (20+ min)12$1,030$74

2019: 16 services

Original Medicare services billed in 2019
Injection, aflibercept, 1 mg163$1,298,498None
Injection, ranibizumab, 0.1 mg86$625,116None
Injection of drug into eye270$137,143$92
Established patient problem focused exam of visual system351$126,928$84
Imaging of retina486$73,337$40
Established patient complete exam of visual system410$67,248$108
New patient visit (45+ min)164$22,879$140
Exam of retinal blood vessels using a special camera after injection of a dye193$22,328$92
Photography of the retina302$21,595$47
Compounded drug, not otherwise classified43$12,637None
Removal of eye fluid (vitreous) between lens and retina14$10,898$778
Destruction of leaking blood vessels of retina using laser16$7,301$332
Examination of eye by ophthalmoscope with retinal drawing67$2,734$24
2d ultrasound scan of eye tissue and structures24$2,319$59
Short return visit (20+ min)18$1,498$68
Examination of eye by ophthalmoscope with retinal drawing27$889$27

2018: 16 services

Original Medicare services billed in 2018
Injection, aflibercept, 1 mg108$957,250None
Injection, ranibizumab, 0.1 mg105$889,064None
Injection of drug into eye287$138,516$88
Established patient problem focused exam of visual system350$114,199$78
Established patient complete exam of visual system511$78,229$101
Imaging of retina533$72,654$38
New patient visit (45+ min)201$26,515$132
Photography of the retina339$26,110$50
Exam of retinal blood vessels using a special camera after injection of a dye232$24,833$82
Compounded drug, not otherwise classified65$17,562None
Destruction of leaking blood vessels of retina using laser27$12,851$313
Photocoagulation treatment to prevent detachment of retina11$5,189$472
Examination of eye by ophthalmoscope with retinal drawing76$3,124$22
Examination of eye by ophthalmoscope with retinal drawing51$2,063$25
Short return visit (20+ min)16$1,298$65
2d ultrasound scan of eye tissue and structures15$1,063$66

2017: 15 services

Original Medicare services billed in 2017
Injection, aflibercept, 1 mg94$863,139None
Injection, ranibizumab, 0.1 mg78$684,155None
Injection of drug into eye253$123,337$88
Established patient problem focused exam of visual system306$93,601$77
Established patient complete exam of visual system479$77,800$99
Imaging of retina426$62,595$38
Photography of the retina317$28,769$62
New patient visit (45+ min)151$19,065$126
Exam of retinal blood vessels using a special camera after injection of a dye196$18,577$71
Compounded drug, not otherwise classified89$17,902None
Destruction of leaking blood vessels of retina using laser18$6,495$282
Short return visit (20+ min)34$2,874$67
Examination of eye by ophthalmoscope with retinal drawing62$2,477$22
2d ultrasound scan of eye tissue and structures19$2,126$82
Examination of eye by ophthalmoscope with retinal drawing35$1,141$24

2016: 16 services

Original Medicare services billed in 2016
Injection, aflibercept, 1 mg83$772,129None
Injection, ranibizumab, 0.1 mg44$346,345None
Injection of drug into eye258$132,818$89
Established patient complete exam of visual system477$87,129$102
Established patient problem focused exam of visual system276$83,541$76
Imaging of retina418$70,146$41
Exam of retinal blood vessels using a special camera after injection of a dye205$55,371$98
Compounded drug, not otherwise classified140$40,003None
Photography of the retina311$32,211$68
New patient visit (45+ min)146$18,981$130
Removal of membrane of retina with removal of internal limiting membrane of retina14$14,658$1,047
Destruction of leaking blood vessels of retina using laser17$10,221$310
Examination of eye by ophthalmoscope with retinal drawing55$2,475$22
2d ultrasound scan of eye tissue and structures12$1,571$83
Short return visit (20+ min)21$1,390$63
Examination of eye by ophthalmoscope with retinal drawing33$1,160$25

2015: 19 services

Original Medicare services billed in 2015
Injection, aflibercept, 1 mg72$625,380None
Injection, ranibizumab, 0.1 mg41$348,913None
Injection of drug into eye246$114,698$93
Established patient complete exam of visual system501$82,862$103
Established patient problem focused exam of visual system260$68,990$77
Imaging of retina458$64,909$42
Exam of retinal blood vessels using a special camera after injection of a dye218$57,194$101
Photography of the retina298$27,396$70
New patient visit (45+ min)186$25,814$139
Destruction of leaking blood vessels of retina using laser18$20,506$932
Unclassified biologics117$19,730None
Removal of membrane of retina with removal of internal limiting membrane of retina11$11,955$1,087
Compounded Drug, Not Otherwise Classified92$9,224$55
Destruction of growth of retina using a laser11$7,348$490
Photocoagulation treatment to prevent detachment of retina11$5,867$489
Examination of eye by ophthalmoscope with retinal drawing83$3,670$23
Examination of eye by ophthalmoscope with retinal drawing55$2,339$25
2d ultrasound scan of eye tissue and structures20$2,328$86
Short return visit (20+ min)31$2,237$62

2014: 17 services

Original Medicare services billed in 2014
Injection, aflibercept, 1 mg63$497,864None
Injection, ranibizumab, 0.1 mg62$401,567None
Injection of drug into eye222$98,315$92
Established patient complete exam of visual system451$91,655$106
Imaging of retina423$53,657$42
Exam of retinal blood vessels using a special camera after injection of a dye211$49,737$100
Destruction of leaking blood vessels of retina using laser30$34,081$921
Established patient problem focused exam of visual system213$28,037$76
Photography of the retina293$27,017$70
New patient visit (45+ min)186$26,371$142
Unclassified biologics119$21,609None
Removal of membrane of retina with removal of internal limiting membrane of retina13$18,650$1,435
Destruction of growth of retina using a laser18$9,823$491
Examination of eye by ophthalmoscope with retinal drawing92$3,158$25
Examination of eye by ophthalmoscope with retinal drawing76$2,485$23
Short return visit (20+ min)31$2,260$66
2d ultrasound scan of eye tissue and structures18$2,166$87

2013: 18 services

Original Medicare services billed in 2013
Injection, ranibizumab, 0.1 mg54$373,822None
Injection, aflibercept, 1 mg39$333,187None
Injection of drug into eye197$79,504$88
Established patient complete exam of visual system359$49,341$99
Imaging of retina419$49,126$42
Exam of retinal blood vessels using a special camera after injection of a dye204$43,803$103
Established patient problem focused exam of visual system204$31,943$77
Destruction of leaking blood vessels of retina using laser20$27,086$934
New patient visit (45+ min)189$27,083$143
Photography of the retina274$22,641$69
Unclassified biologics110$19,635None
Short return visit (20+ min)148$12,510$60
Destruction of growth of retina using a laser20$11,227$488
2d ultrasound scan of eye tissue and structures18$2,330$86
Examination of eye by ophthalmoscope with retinal drawing80$1,994$25
Examination of eye by ophthalmoscope with retinal drawing48$1,348$22
Short return visit29$1,343$40
Imaging of optic nerve16$711$42

Medicaid work

$378,690 in 2024

Medicaid paid $378,690 for 1,140 billed services this clinician did in 2024, up to 32 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Aflibercept injection141$210,771
Intravitreal injection of a pharmacologic agent (separate procedure)378$139,909
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina419$12,882
Return visit (30+ min)113$9,515
Short return visit (20+ min)77$4,857
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT12$756
Medicaid work by year
20241,140632$378,690
20231,383838$477,423
20221,293631$530,010
2021807523$95,984
2020491520$186,994
2019931421$182,098
2018473320$73,786
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Aflibercept injection181$290,547
Intravitreal injection of a pharmacologic agent (separate procedure)476$161,685
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina497$13,809
Return visit (30+ min)94$4,434
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient64$2,721
Injection, bevacizumab, 10 mg46$2,215
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI13$1,604
Short return visit (20+ min)12$408

2022

Largest Medicaid services in 2022
Aflibercept injection242$385,120
Intravitreal injection of a pharmacologic agent (separate procedure)368$123,109
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina512$13,327
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient145$6,929
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI12$1,116
Return visit (30+ min)14$409

2021

Largest Medicaid services in 2021
Intravitreal injection of a pharmacologic agent (separate procedure)374$82,133
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina318$5,868
Aflibercept injection17$4,036
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient85$3,666
Return visit (30+ min)13$281

2020

Largest Medicaid services in 2020
Aflibercept injection45$103,935
Intravitreal injection of a pharmacologic agent (separate procedure)192$74,271
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient127$5,305
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina99$1,901
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT28$1,581

2019

Largest Medicaid services in 2019
Aflibercept injection40$92,713
Intravitreal injection of a pharmacologic agent (separate procedure)298$72,858
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient289$8,487
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina304$8,040

2018

Largest Medicaid services in 2018
Intravitreal injection of a pharmacologic agent (separate procedure)200$65,282
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient157$5,656
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina116$2,848

Drugs they prescribed that Part D paid

$9,328

Pharmacies billed $9,328 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 168) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.

112 generic and 56 brand-name prescriptions · $9,328 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Prednisolone Acetate45$2,785$62
Neomycin-Polymyxin-Dexameth52$559$11
Ketorolac Tromethamine22$463$21
Latanoprost16$69$4

Year by year

Part D prescribing by year
2024168670% (0)33%$9,328
2023138560% (0)28%$4,743
2022166580% (0)25%$5,524
202115059None40%$7,763
202016055None53%$9,212
2019193720% (0)55%$10,945
201819776None49%$16,896
201718067None57%$11,910
2016141630% (0)42%$8,799
201512962None38%$8,561
201412053NoneNone$29,711
201317560NoneNone$6,719

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 3 drugs

Part D drugs prescribed in 2023
Prednisolone Acetate38$2,064$54
Neomycin-Polymyxin-Dexameth46$609$13
Ketorolac Tromethamine20$522$26

2022: 4 drugs

Part D drugs prescribed in 2022
Prednisolone Acetate35$2,003$57
Ketorolac Tromethamine36$1,448$40
Neomycin-Polymyxin-Dexameth58$786$14
Latanoprost12$78$7

2021: 4 drugs

Part D drugs prescribed in 2021
Durezol14$3,285$235
Prednisolone Acetate40$1,809$45
Neomycin-Polymyxin-Dexameth60$948$16
Ketorolac Tromethamine24$716$30

2020: 4 drugs

Part D drugs prescribed in 2020
Durezol18$4,616$256
Prednisolone Acetate46$1,745$38
Ketorolac Tromethamine21$836$40
Neomycin-Polymyxin-Dexameth43$721$17

2019: 4 drugs

Part D drugs prescribed in 2019
Durezol22$4,949$225
Prednisolone Acetate57$2,141$38
Ketorolac Tromethamine33$1,255$38
Neomycin-Polymyxin-Dexameth48$828$17

2018: 4 drugs

Part D drugs prescribed in 2018
Durezol19$4,557$240
Combigan11$1,882$171
Prednisolone Acetate31$1,065$34
Neomycin-Polymyxin-Dexameth64$900$14

2017: 4 drugs

Part D drugs prescribed in 2017
Durezol29$5,046$174
Prednisolone Acetate35$1,533$44
Neomycin-Polymyxin-Dexameth51$698$14
Ketorolac Tromethamine14$596$43

2016: 3 drugs

Part D drugs prescribed in 2016
Durezol13$2,323$179
Neomycin-Polymyxin-Dexameth54$825$15
Prednisolone Acetate20$797$40

2015: 3 drugs

Part D drugs prescribed in 2015
Durezol19$3,516$185
Neomycin-Polymyxin-Dexameth61$1,022$17
Prednisolone Acetate17$766$45

2014: 2 drugs

Part D drugs prescribed in 2014
Prednisolone Acetate22$1,126$51
Neomycin-Polymyxin-Dexameth40$700$17

2013: 3 drugs

Part D drugs prescribed in 2013
Neomycin-Polymyxin-Dexameth32$615$19
Prednisolone Acetate30$542$18
Venlafaxine Hcl Er16$220$14

Money from drug and device companies

$10,310 in 2025

Industry payments by year
2025410$9,525$10,310
2024613$14,046$14,458
2023520$25,702$27,435
2022512$18,424$18,633
2021511$4,945$5,417
2020512$13,328$13,660
2019848$56,473$60,276

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GenentechVabysmo$4,569
2 payments
  • Meals · 2025-10-16 · $189
  • Consulting for Vabysmo · 2025-08-27 · $4,380
Genentech USANone$3,937
4 payments
  • Travel · 2025-07-31 · $38
  • Meals · 2025-07-31 · $120
  • Consulting · 2025-07-31 · $3,445
  • Travel · 2025-07-31 · $334
AbbvieOzurdex$1,700
2 payments
  • Consulting for Ozurdex · 2025-11-03 · $850
  • Consulting · 2025-08-25 · $850
Ocular TherapeutixDextenza$104
2 payments
  • Meals for Dextenza · 2025-10-17 · $67
  • Meals for Dextenza · 2025-08-01 · $38
See all 10 published payments
Every published payment
AbbvieConsulting · 2025-11-03Ozurdex$850
Ocular TherapeutixMeals · 2025-10-17Dextenza$67
GenentechMeals · 2025-10-16None$189
GenentechConsulting · 2025-08-27Vabysmo$4,380
AbbvieConsulting · 2025-08-25None$850
Ocular TherapeutixMeals · 2025-08-01Dextenza$38
Genentech USATravel · 2025-07-31None$38
Genentech USAMeals · 2025-07-31None$120
Genentech USAConsulting · 2025-07-31None$3,445
Genentech USATravel · 2025-07-31None$334
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $14,458

Payments by company in 2024
Regeneron PharmaceuticalsEylea Hd$6,783
5 payments
  • Consulting for Eylea Hd · 2024-12-13 · $2,210
  • Consulting for Eylea Hd · 2024-12-13 · $3,315
  • Meals for Eylea Hd · 2024-10-14 · $131
  • Consulting for Eylea Hd · 2024-08-14 · $1,105
  • Meals for Eylea Hd · 2024-02-10 · $22
AbbvieOzurdex$3,896
3 payments
  • Consulting · 2024-12-30 · $1,700
  • Consulting · 2024-08-13 · $840
  • Consulting for Ozurdex · 2024-04-29 · $1,356
GenentechVabysmo$2,520
1 payment
  • Consulting for Vabysmo · 2024-10-11 · $2,520
Bausch & Lomb AmericasXipere$1,022
2 payments
  • Meals for Xipere · 2024-11-23 · $22
  • Consulting for Xipere · 2024-11-07 · $1,000
Alcon VisionClareon$124
1 payment
  • Meals for Clareon · 2024-09-27 · $124
RxSightRxsight Contact Lens$114
1 payment
  • Meals for Rxsight Contact Lens · 2024-06-12 · $114

2023: $27,435

Payments by company in 2023
Regeneron PharmaceuticalsEylea$8,615
6 payments
  • Consulting for Eylea · 2023-09-08 · $3,703
  • Consulting for Eylea · 2023-09-08 · $1,058
  • Meals for Eylea · 2023-08-21 · $50
  • Meals for Eylea · 2023-07-30 · $27
  • Consulting for Eylea Hd · 2023-06-23 · $3,703
  • Meals for Eylea · 2023-04-03 · $74
AbbvieNone$8,593
8 payments
  • Consulting · 2023-11-22 · $7,750
  • Meals · 2023-10-10 · $21
  • Meals · 2023-10-10 · $12
  • Travel · 2023-10-10 · $261
  • Meals · 2023-10-10 · $12
  • Travel · 2023-10-10 · $264
  • Meals · 2023-10-10 · $21
  • Travel · 2023-10-09 · $253
Regeneron Healthcare SolutionsEylea$6,938
4 payments
  • Consulting for Eylea · 2023-12-08 · $2,116
  • Travel for Eylea · 2023-11-17 · $461
  • Consulting for Eylea · 2023-11-17 · $4,232
  • Meals for Eylea · 2023-10-06 · $129
GenentechVabysmo$3,140
1 payment
  • Consulting for Vabysmo · 2023-08-18 · $3,140
Genentech USANone$149
1 payment
  • Meals · 2023-11-25 · $149

2022: $18,633

Payments by company in 2022
GenentechVabysmo$7,650
5 payments
  • Consulting · 2022-12-19 · $393
  • Consulting · 2022-12-19 · $393
  • Consulting for Vabysmo · 2022-08-27 · $2,940
  • Consulting · 2022-08-02 · $1,963
  • Consulting · 2022-08-02 · $1,963
Apellis PharmaceuticalsNone$4,550
1 payment
  • Consulting · 2022-01-21 · $4,550
Bausch & Lomb AmericasXipere$3,197
3 payments
  • Consulting · 2022-10-19 · $1,650
  • Meals · 2022-10-02 · $147
  • Consulting for Xipere · 2022-02-17 · $1,400
Regeneron Healthcare SolutionsEylea$3,174
1 payment
  • Consulting for Eylea · 2022-08-26 · $3,174
Regeneron PharmaceuticalsEylea$62
2 payments
  • Meals for Eylea · 2022-12-20 · $29
  • Meals for Eylea · 2022-08-30 · $34

2021: $5,417

Payments by company in 2021
Bausch & Lomb a division of Bausch Health USXipere$2,250
3 payments
  • Consulting for Xipere · 2021-12-02 · $750
  • Consulting for Xipere · 2021-10-28 · $750
  • Consulting for Xipere · 2021-02-09 · $750
Genentech USALucentis$1,856
5 payments
  • Consulting · 2021-09-29 · $785
  • Meals for Lucentis · 2021-08-19 · $124
  • Meals for Lucentis · 2021-07-22 · $136
  • Meals for Lucentis · 2021-07-16 · $26
  • Consulting for Lucentis · 2021-06-30 · $785
Aerie PharmaceuticalsNone$1,125
1 payment
  • Consulting · 2021-01-12 · $1,125
Carl Zeiss Meditec USANone$125
1 payment
  • Meals · 2021-11-14 · $125
Alimera SciencesIluvien$61
1 payment
  • Meals for Iluvien · 2021-06-23 · $61

2020: $13,660

Payments by company in 2020
Merck Sharp & DohmeNone$5,790
5 payments
  • Travel · 2020-03-13 · $150
  • Consulting · 2020-03-13 · $5,500
  • Meals · 2020-01-16 · $40
  • Meals · 2020-01-16 · $50
  • Meals · 2020-01-16 · $50
Aerie PharmaceuticalsNone$3,188
2 payments
  • Consulting · 2020-11-03 · $1,313
  • Consulting · 2020-09-17 · $1,875
Genentech USALucentis$3,158
3 payments
  • Consulting for Lucentis · 2020-12-21 · $2,355
  • Consulting for Lucentis · 2020-09-30 · $785
  • Meals for Lucentis · 2020-02-26 · $18
Bausch & Lomb a division of Bausch Health USXipere$1,500
1 payment
  • Consulting for Xipere · 2020-07-10 · $1,500
Regeneron Healthcare SolutionsEylea$24
1 payment
  • Meals for Eylea · 2020-03-09 · $24

2019: $60,276

Payments by company in 2019
AllerganOzurdex$22,154
21 payments
  • Consulting · 2019-10-22 · $9,600
  • Travel · 2019-09-25 · $30
  • Meals · 2019-09-25 · $216
  • Travel · 2019-09-25 · $20
  • Travel · 2019-09-25 · $220
  • Travel · 2019-09-25 · $242
  • Meals for Ozurdex · 2019-08-16 · $28
  • Meals · 2019-08-16 · $104
  • Meals · 2019-08-16 · $89
  • Meals · 2019-08-16 · $147
  • Meals · 2019-08-16 · $128
  • Meals · 2019-08-16 · $41
  • Consulting · 2019-08-16 · $10,125
  • Travel · 2019-08-16 · $360
  • Travel · 2019-08-16 · $258
  • Travel · 2019-08-16 · $20
  • Travel · 2019-08-16 · $20
  • Travel · 2019-08-16 · $41
  • Travel · 2019-08-16 · $15
  • Travel · 2019-08-16 · $32
  • Education · 2019-07-14 · $417
F. Hoffmann-La Roche AGLucentis$18,583
7 payments
  • Paid to speak or teach for Lucentis · 2019-12-31 · $1,539
  • Paid to speak or teach for Lucentis · 2019-12-31 · $3,501
  • Paid to speak or teach for Lucentis · 2019-12-31 · $6,425
  • Paid to speak or teach for Lucentis · 2019-09-30 · $248
  • Paid to speak or teach for Lucentis · 2019-06-30 · $5,400
  • Paid to speak or teach for Lucentis · 2019-03-31 · $946
  • Paid to speak or teach for Lucentis · 2019-03-31 · $526
Regeneron Healthcare SolutionsEylea$15,421
10 payments
  • Consulting for Eylea · 2019-12-19 · $1,020
  • Consulting for Eylea · 2019-11-14 · $3,570
  • Meals for Eylea · 2019-10-13 · $74
  • Consulting for Eylea · 2019-03-28 · $10,200
  • Travel for Eylea · 2019-03-28 · $36
  • Meals for Eylea · 2019-03-28 · $13
  • Travel for Eylea · 2019-02-07 · $160
  • Travel for Eylea · 2019-02-07 · $135
  • Travel for Eylea · 2019-01-21 · $35
  • Travel for Eylea · 2019-01-21 · $178
Aerie PharmaceuticalsNone$3,375
1 payment
  • Consulting · 2019-12-05 · $3,375
Genentech USALucentis$316
3 payments
  • Meals · 2019-10-11 · $172
  • Meals for Lucentis · 2019-07-01 · $21
  • Meals for Lucentis · 2019-03-12 · $123
GenentechLucentis$271
3 payments
  • Meals for Lucentis · 2019-09-10 · $72
  • Meals for Lucentis · 2019-02-19 · $150
  • Meals for Lucentis · 2019-01-07 · $50
Hoffmann-La RocheNon-Covered Product$107
1 payment
  • Meals for Non-Covered Product · 2019-03-21 · $107
Novartis PharmaceuticalsBeovu$49
2 payments
  • Meals · 2019-03-09 · $26
  • Meals for Beovu · 2019-02-14 · $24

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Genentech, Inc. · Va2 Phiii Rhine · 2020Their institution$296,664
Genentech, Inc. · Va2 Phiii Rhine · 2019Their institution$182,732
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2021Their institution$129,179
Genentech, Inc. · Iamd Observational Study · 2023Their institution$120,736
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2024Their institution$119,805
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022Their institution$105,747
Apellis Pharmaceuticals, Inc. · Study To Compare the Efficacy and Safety of Intravitreal Apl-2 Therapy With Sham Injections in Patients With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration · 2022Their institution$88,830
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2023Their institution$77,471
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2022Their institution$70,964
Genentech, Inc. · A Phase III Study To Investigate Ro7200220 in Patients With Uveitic Macular Edema · 2025Their institution$68,521
Genentech, Inc. · Ph 2 Open Label Extension of Ahtra1 in Ga · 2022Their institution$64,571
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2020Their institution$62,555
Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2023Their institution$59,330
Genentech, Inc. · Iamd Observational Study · 2025Their institution$59,141
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2022Their institution$57,950
Genentech, Inc. · Va2 Phiii Rhine · 2021Their institution$55,975
Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2024Their institution$54,234
Genentech, Inc. · Iamd Observational Study · 2024Their institution$51,870
Genentech, Inc. · A Phase III Study To Investigate Ro7200220 in Patients With Uveitic Macular Edema · 2024Their institution$51,299
Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2021Their institution$41,657
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023Their institution$41,127
Genentech, Inc. · Va2 Phiii Rhine · 2022Their institution$38,391
Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2022Their institution$33,022
EyePoint Pharmaceuticals US, Inc. · A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), in Subjects With Wet Amd · 2022Their institution$29,638
Genentech, Inc. · Ph 2 Open Label Extension of Ahtra1 in Ga · 2023Their institution$27,219
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2023Their institution$25,663
EyePoint Pharmaceuticals US, Inc. · A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), in Subjects With Wet Amd · 2021Their institution$24,153
Allergan Inc. · Phase 2 - Evaluation of Abicipar Pegol in Patients With Namd 1771-201-008 · 2019Their institution$22,210
Genentech, Inc. · Ph1 Sad of Il33 in Geographic Atrophy · 2022Their institution$22,011
EyePoint Pharmaceuticals US, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of A Fluocinolone Acetonide (Fa) Intravitreal 0.05 Mg Insert (Yutiq 0.05 Mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye · 2022Their institution$19,938
Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2025Their institution$15,278
Genentech, Inc. · A Phase III Study To Investigate Ro7200220 in Patients With Uveitic Macular Edema · 2023Their institution$13,518
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2021Their institution$13,186
Notal Vision, Inc. · Nrich · 2025Their institution$10,020
Genentech, Inc. · Belvedere · 2023Their institution$10,000
Genentech, Inc. · Ph 2 Open Label Extension of Ahtra1 in Ga · 2024Their institution$9,746
Genentech, Inc. · Ph1 Sad of Il33 in Geographic Atrophy · 2021Their institution$8,267
Allergan Inc. · A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related Macular Degeneration · 2019Their institution$8,103
ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy · 2025Their institution$8,062
Genentech, Inc. · Safety and Tolerability Study of Ro7171009 in Participants With Geographic Atrophy Ga Secondary To Age-Related Macular Degeneration Amd · 2019Their institution$6,279
Regeneron Pharmaceuticals, Inc. · Health Economics Outcome Research Related To Opthalmology · 2024This clinician$5,325
Genentech, Inc. · Ph1 Sad of Il33 in Geographic Atrophy · 2023Their institution$5,195
EyePoint Pharmaceuticals US, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of A Fluocinolone Acetonide (Fa) Intravitreal 0.05 Mg Insert (Yutiq 0.05 Mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye · 2023Their institution$4,603
F. Hoffmann-La Roche AG · Lucentis Dosing Retreatment · 2020This clinician$4,062
Genentech, Inc. · Ph I of A Htra1 in Ga Secondary To Amd · 2019Their institution$3,772
F. Hoffmann-La Roche AG · Va2 Phiii Yosemite · 2025This clinician$3,163
Boehringer Ingelheim International GmbH · Jade: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding Study To Evaluate the Efficacy and Safety of Bi 1584862 · 2025Their institution$2,984
F. Hoffmann-La Roche AG · Va2 Phiii Yosemite · 2024This clinician$1,938
Alimera Sciences, Inc. · Paladin · 2019Their institution$1,073
Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2020This clinician$729
Regeneron Pharmaceuticals, Inc. · Health Economics and Outcomes Research (Heor) · 2020This clinician$616
F. Hoffmann-La Roche AG · Il-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Phase 1 Dovetail, and Phase 3 Meerkat and Sandcat Trials · 2024This clinician$600
F. Hoffmann-La Roche AG · Faretina-Dme Real-World Injection Frequency, Visual Acuity and Anatomical Outcomes ?12-Month Follow Up · 2023This clinician$359
ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy (Rgx-314 Srltfu) · 2025Their institution$339
Boehringer Ingelheim Pharmaceuticals, Inc. · Jade: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding Study To Evaluate the Efficacy and Safety of Bi 1584862 · 2025Their institution$150

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
100.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1912002106
Licence
CA A87255California A87255: Current · expires 2028-05-31
Trained
Duke University School of Medicine, 2002
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207W00000X (207W00000X)
Mailing address
2485 Hospital Dr, Ste 200, Mountain View, CA, 94040
NPI first listed
2006-09-13
NPI last updated
2013-03-13

This is when the NPI record was last certified, not a medical board exam.